I tend to disagree
I have always felt to distribute and market by themselves was a flawed approach.
AHZ is a small fish in an ocean of big medical players.
And really I think ATM Cardiocel is all they are selling in that division of the company .
Licence it to the big boys where they have reps that sell many products. Clip the ticket on each sale
Concentrate on pushing out the research and data to date on Cardiocel if it's the gold standard . The big boys will market it to better effect
Ann: Appendix 4C - quarterly, page-254
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.15 |
Change
0.350(2.97%) |
Mkt cap ! $256.8M | |||
| Open | High | Low | Value | Volume |
| $11.80 | $12.15 | $11.21 | $376.0K | 32.22K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 139 | $12.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.15 | 830 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |